330 likes | 663 Views
IPEC/PQG Excipient GMPs guide. The organisationsBackgroundKey milestonesJoint charter (governance and oversight)Development process Major improvementsBenefits to Industry and RegulatorsImplementation Strategy. IPEC . International Pharmaceutical Excipients CouncilFormed in 1991 by manufact
E N D
1. Launch of
IPEC/PQG Excipient GMPs guide
Kevin McGlue, Steve Moss
2. IPEC/PQG Excipient GMPs guide The organisations
Background
Key milestones
Joint charter (governance and oversight)
Development process
Major improvements
Benefits to Industry and Regulators
Implementation Strategy
3. IPEC International Pharmaceutical Excipients Council
Formed in 1991 by manufacturers and end-users of excipients
Three associations covering the US, Europe and Japan
Objective: to contribute to the development and harmonisation of international excipient standards, the introduction of useful new excipients to the marketplace and the development of good manufacturing practice for excipients.
First published GMP Guide for Bulk Pharmaceutical Excipients in 1995, revised in 2001 to align with ISO 9001:2000.
4. PQG Institute of Quality Assurance, Pharmaceutical Quality Group
Formed in UK in1977
Key objective: To promote the development of a consistent approach to pharmaceutical quality and good manufacturing practice.
In 1990 published three codes of practice - pharmaceutical raw materials, printed and contact packaging materials. In 1995 revised and integrated these with ISO 9002:1994.
Raw materials code revised and reissued as PS 9100:2002 Pharmaceutical excipients, an application standard and GMP guide for pharmaceutical excipients.
5. Background to the joint guide Increased focus on Excipient GMPs led to the need for a single international guide
June 2002
IPEC Europe, IPEC Americas and PQG signed a letter of intent in committing to collaborate on a Baseline GMP guide for excipients
December 2002
Joint charter issued
Explain JPEC
Specific regulatory situation in Japan means JPEC support the initiative but cant participate. They were observers at an initial meeting.Explain JPEC
Specific regulatory situation in Japan means JPEC support the initiative but cant participate. They were observers at an initial meeting.
6. Joint Charter Purpose To produce a joint international GMP guide for excipients, which will build upon and replace the two groups existing documents. It will be aligned to ISO 9001:2000 and include a baseline (minimum) GMP for excipients.
During development of the document excipients used in more critical applications will be considered for inclusion in Appendices, as appropriate
The document will also provide the basis for a certification scheme for excipient suppliers separate from the basic GMP guideline.
7. Joint Charter - Boundaries Includes:
GMP guide for excipients for all pharmaceutical products
GMP guide could be used for certification in subsequent phase
Future inclusions include audit and training guides
Excludes:
Sterile excipients
Active Pharmaceutical Ingredients
Products of biotechnology
Certification process
8. Joint Charter - Structure Steering Committee (Sponsors):
2 Members IPEC-Europe
2 Members IPEC-Americas
2 Members PQG
Team Members (Core team):
Six members, two from each organisation
9. Joint Charter Some Stakeholders 1 Association of the British Pharmaceutical Industry,
CEFIC,
Certification bodies for PQG Scheme,
European Federation of Pharmaceutical Industry Associations,
Excipient suppliers,
European Community DG3,
European Pharmacopoeia,
International Conference on Harmonisation,
IPEC-Europe, IPEC-Americas,
International Pharmaceutical Excipients Auditing Inc (IPEA),
10. Joint Charter Some Stakeholders 2 Institute of Quality Assurance
PQG committee,
Pharmaceutical companies,
Pharmaceutical Research and Manufacturers of America (PhRMA),
Regulatory bodies (Food & Drug Administration, Medicines & Healthcare Products Regulatory Authority etc),
United States Pharmacopoeia,
World Health Organisation,
Japanese Pharmaceutical Excipients Council (JPEC) - as an observer
11. Key milestones Initial meeting
Review process
Draft new guide
Consultations and review
Final review
Publication and launch
12. Initial team meeting 23rd January 2003
Key principles
Project timescales
ISO 9001 format
Overall document structure
Consultation and review process
13. Initial review process Started March 2003
Reviewed detail of key source documents
PQG, IPEC, ISO 9001, ICH Q7a
Compared all the clauses in a matrix
Chose the most appropriate guidance appropriate for excipients
Resolved differences
Significant update in line with current thinking
Involved careful consideration and deliberation
14. Drafted NEW guide Q2 2003 to Q1 2004
Improved assignment to ISO sections
more logical flow and improved readability
Key areas improved with significant rewriting include:
structure & responsibility of quality unit, product release, validation, stability, change control, GMP principles, auditing considerations
Continuous processing accounted for throughout
E.g. bulk materials, batch documentation and release
15. Further development of guide Q2 to Q3 2004
Many multi-day meetings in UK, US, France
Continual adaptation to the prevailing changing environment
Maintained focus on developing voluntary baseline guidance
Potentially with need for additional guidance for specialist applications
16. Consultation and review Q4 2004 to Q3 2005
1. Members comment x2 (some external bodies eg EFPIA via members)
Consolidated comments (100s!) to produce approved draft for external release
2. External circulation - Key organisations including regulatory authorities, trade organisations and other stakeholders
Consolidated comments
3. Issued to members for final comment
Consolidated comments to produce final draft
4. Comprehensive QC checks x2 teams
Corrected to produce draft for printing
17. Publication & printing Q4 2005
Hardcopy
US English by IPEC Americas
letter and pocket versions
UK English by IPEC Europe
A4 and pocket versions
Electronic
A4/letter downloadable from websites
18.
Thanks to the GMP/Partners groups and the wider membership of each organisation for help and excellent contributions!
19. Major improvements 1 Better assignment to ISO sections to give more logical flow and improved readability
Accurate and legible wording
Appropriate guidance for excipients
Key awkward clauses addressed e.g. stability, validation, change control
Included continuous processing - particularly the impact on batch definition and records
20. Major improvements 2 Improved auditing considerations - GMP principles and applications
Harmonized glossary - rationalised to ICH where possible
Consistent use of terminology e.g. document, records; rework, reprocess
Removed ambiguity for international use (e.g. recall/retrieval; batch/lot)
21. Benefits to Industry and Regulators 1. Broad acceptance
Document critically reviewed by all stakeholders to obtain consensus
Well received by excipients industry and by pharmaceutical companies and their industry bodies, regulators EMEA and EC - suggests balance is appropriate
Overall good collaboration between US and Europe resulting in international acceptance
22. Benefits to Industry and Regulators 1. Broad acceptance (contd)
Participation and involvement with many good comments from many members, organisations, etc
Working with EC - new guide helping focus discussions and benchmarking appropriate principles which may become law for certain excipients
23. Benefits to Industry and Regulators 2. Ease of application
Builds additional GMP guidance onto the ISO framework
commonly used by the industry already
Practical guidance for excipient manufacturer
balancing pharmaceutical customers' expectations with usual constraints
Clear unambiguous wording
24. Benefits to Industry and Regulators 2. Ease of application (contd)
Provides common guide eliminating the need for multiple customers' requirements.
Manufacturer applies common & appropriate standard, quality systems & controls
User provides common expectation of what is appropriate for excipient manufacturers, audits
Clearly differentiates guidance for excipients
more than ISO 9001
more appropriate than ICH Q7a
25. Implementation Strategy Launch events
IPEC Americas Orlando, 26th January 2006
PQG London, 7th February 2006
IPEC Europe Cannes, 9th February 2006
26. Additional copies available now
ipec.org and pqg.org
Order forms for printed copies
Members download free
Please spread the word!